Cost-Effectiveness and Cost-Utility Analysis of Tongxinluo Capsules Compared With Conventional Therapy for the Treatment of Acute Myocardial Infarction.

ABSTRACT:

Aim

Tongxinluo (TXL) capsule, a traditional Chinese medicine compound, has proven effective in acute myocardial infarction (AMI), but its cost-effectiveness is unclear.

Methods

This economic evaluation utilized individual data from clinical trials to compare major adverse cardiac and cerebrovascular events (MACCEs) at 30 days and quality-adjusted life years (QALYs) at 1 year between an intervention group (TXL combined with conventional therapy) and the control group (placebo plus conventional therapy), from a healthcare perspective. A lifetime cost-utility analysis (CUA) was conducted using a Markov model, and sensitivity analyses were performed to evaluate the robustness of the results.

Results

A total of 3777 patients (TXL: 1889; placebo: 1888) were included in the

SUBMITTER: Liu G 

PROVIDER: S-EPMC12506947 | biostudies-literature | 2025 Sep

REPOSITORIES: biostudies-literature